title: Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells.
abstract: BACKGROUND
  MYCN amplification is highly associated with malignancy and correlates with poor prognosis in patients with neuroblastoma.
  
  
  METHODS
  We developed a novel liposome-MYCN siRNA-folic acid complex, and the transfection efficacy was measured in LA-N-5 cells by cy-3 fluorescence density in each microgram of protein from the transfected cell lysate. MYCN expression and cell growth were studied with quantitative RT-PCR and MTT assays, and the expression of MYCN protein was studied with Western blot, respectively. An SCID mouse model with subcutaneous LA-N-5 xenografted tumor was established. The animals were divided into four groups (n = 5) and they were peritoneally injected with liposome-encapsulated MYCN siRNA (siRNA 125 μg/kg/day), lipid-encapsulated control siRNA, MYCN siRNA, or liposome only, respectively, for 5 consecutive days. The animals were killed 24 h after the last injection, and the expression of MYCN mRNA in tumor tissue was detected by RT-PCR.
  
  
  RESULTS
  Our results are as follows: the transfect efficacy reached 1808.5 ± 140.2 pg siRNA/μg protein in LA-N-5 lysates after treatment with 100 nmol/L MYCN siRNA encapsulated with lipid, and fluorescence could be visualized in 92% of LA-N-5 cells after transfection. At 72 h post-transfection, MYCN mRNA expression in LA-N-5 cells was downregulated by 79.2%, MYCN protein was downregulated by 71.3% and cell growth was inhibited by 66.2%, as measured by MTT assay. In the in vivo study, MYCN mRNA expression was knocked down 53.1% in tumor tissues with injection of liposome-encapsulated MYCN siRNA as compared to control siRNA.
  
  
  CONCLUSIONS
  These results suggest that targeted delivery of MYCN siRNA by folate receptor-targeted lipid vesicles into LA-N-5 cells is efficacious and capable of suppressing MYCN mRNA expression both in vitro and in vivo.
authors.affiliation: Department of Pediatrics, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Feng
authors.forename: Tianyou
authors.initials: T
authors.lastname: Wang
authors.forename: Ruihong
authors.initials: R
authors.lastname: Tang
authors.forename: Jianwen
authors.initials: J
authors.lastname: Wang
authors.forename: Hui
authors.initials: H
authors.lastname: Long
authors.forename: Xiaoning
authors.initials: X
authors.lastname: Gao
authors.forename: Suoqin
authors.initials: S
authors.lastname: Tang
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D058973:Folate Receptors, GPI-Anchored; D020868:Gene Silencing; D006801:Humans; D008081:Liposomes; D051379:Mice; D016513:Mice, SCID; D058990:Molecular Targeted Therapy; D000071447:N-Myc Proto-Oncogene Protein; D009447:Neuroblastoma / Q000188:drug therapy*; D009687:Nuclear Proteins / Q000235:genetics*; D015513:Oncogene Proteins / Q000235:genetics*; D034741:RNA, Small Interfering / Q000627:therapeutic use*; D052416:Targeted Gene Repair; D014162:Transfection
chemical_list: D058973:Folate Receptors, GPI-Anchored; D008081:Liposomes; C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins; D034741:RNA, Small Interfering